Fig. 7: Anti-tumour effects of AECM@PC7A in a humanised CDX model.
From: Neoantigen enriched biomimetic nanovaccine for personalized cancer immunotherapy
a Representative histogram showing HLA-I expression on IFN-γ treated and control MDA-MB-231 cells. b Scheme showing the model construction and the timeline of vaccination. NSG mice were injected intravenously with 5 × 106 human PBMCs for 8 days then inoculated with 2 × 106 MDA-MB-231 cells, followed by two doses of vaccinations. Individual (c) and average (d) tumour growth curves, and mice survival (e) of NSG mice with different treatments (c, d, n = 5 mice/group). f Irradiated cancer cell-reactive IFN-γ+ cells in CD8+ T-cells of PBMCs as determined by ICS (n = 3 mice for AECM@PC7A group, and n = 5 mice for other groups). The frequency of tumour infiltrating human immune cells (g) and CD8+ T-cells (h) at day-28 post tumour inoculation. (g, h, n = 3 mice for AECM@PC7A group, and n = 5 mice for other groups). In (d, f–h, representative data from three independent experiments are presented as means ± s.e.m. Statistical significance was calculated by ordinary one-way ANOVA (d, f–h) and log-rank test (e). Source data are provided as a Source Data file.
